Daré Bioscience's Additional Findings From Exploratory Phase 2B RESPOND Study Of Sildenafil Cream In Women With Sexual Arousal Disorder Achieves Statistical Significance, Clinically Meaningful Improvement In Co-primary Endpoint Assessing Arousal Sensation
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has reported additional findings from its exploratory Phase 2B RESPOND study of Sildenafil Cream in women with sexual arousal disorder. The results showed statistical significance and clinically meaningful improvement in the co-primary endpoint assessing arousal sensation.
November 01, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daré Bioscience's Phase 2B RESPOND study of Sildenafil Cream in women with sexual arousal disorder has achieved statistical significance and clinically meaningful improvement. This could potentially lead to increased investor interest in the company.
The positive results from the Phase 2B RESPOND study of Sildenafil Cream indicate that the product is effective in treating women with sexual arousal disorder. This could potentially lead to increased investor interest in Daré Bioscience, as it suggests that the company's product has a high chance of success in the market. This could potentially lead to increased revenues for the company in the future, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100